Citations

Clear

2429 citation(s) found for "Shah, M".

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR
Tung, Nadine , DeMichele, Angela , Winer, Eric P. , Wright, Jean L. , Recht, Abram , Weiss, Anna C., Tjoe, Judy A., Feldman, Sheldon M. , Smith, Mary Lou , O’Sullivan, Ciara C. , Sardesai, Sagar D., Irvin, W. J., Battelli, Chiara, Krie, Amy, D’Abreo, Nina , Shah, Payal D. , DeMichele, Angela , Prat, Aleix , Winer, Eric , Wright, Jean L , Recht, Abram , Rocque, Gabrielle , O'Sullivan, Ciara Catherine , Tang, Shou-Ching , Modi, Shanu , Bagegni, Nusayba , Krie, Amy K , Telli, Melinda L , Borges, Virginia F , D'Abreo, Nina , Shah, Payal D , Villagrasa, Patricia , Badve, Sunil S , Partridge, Ann H , Miller, Kathy D , Carey, Lisa A , Wolff, Antonio C , Tung, Nadine , Zhao, Fengmin , Weiss, Anna , Tjoe, Judy A., Rocque, Gabrielle B. , Sardesai, Sagar , Modi, Shanu , Irvin, William , Unni, Nisha G , George, Mridula Annette , Telli, Melinda L. , Borges, Virginia F. , Badve, Sunil , Partridge, Ann H. , Miller, Kathy D. , Carey, Lisa A. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-02255 | PMID 42623567 Get It

PURPOSE EA1181 (ClinicalTrials.gov identifier: NCT04266249 ) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)–positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point—3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)—will be reported when data mature. METHODS Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR. RESULTS A total of 2,175 patients were enrolled (781 HER2+/estrogen receptor‑negative [ER–]; 1,394 HER2+/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+/ER– and 32.4% in HER2+/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+/ER– tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables. CONCLUSION Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER– and one third with HER2+/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.
Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease
Greenberg, Steven M. , Iadecola, Costantino , Chou, Sherry , Cogswell, Petrice M, Elkind, Mitchell S.V. , II, William J. Hicks, Le, Caitlin, Levine, Deborah A. , Lipton, Richard B. , Massimo, Lauren, Mohl, Stephanie M. , Snyder, Heather M. , Yaffe, Kristine , Adams, Robert, Agronin, Marc, Atri, Alireza, Bauman, Mary Ann, Bernat, James L., Biffi, Alessandro , Blum, Sonja, Bussiere, Thierry, Carrillo, Maria C., Chiang, Gloria, Cato, Kenrick, Chaitoff, Alexander, Bakken, Suzanne, Schelke, Matthew W. , Cruz‐Flores, Salvador, Derdeyn, Colin, Dhand, Amar, Evans, David A., Gettel, Cameron, Goldstein, Larry B, Grill, Joshua, Kulshrestha, Ambar, Lam, Christine, Lazar, Ronald M. , Li, Hanlin , Madsen, Tracy, Ramanan, Vijay K., McCullough, Louise, Merino, José G., Orjuela, Karen, Guo, Michael, Messe, Steve, Tubiello, Maggie, Ruff, Christian T., Selim, Magdy, Sha, Sharon J., Sheth, Kevin, Stamm, Brian, Buckwalter, Marion, Skylar-Scott, Irina, Lavretsky, Helen, Saver, Jeffrey, Rabinovici, Gil D., VandeVrede, Lawren, Goyal, Manu S., Weisman, David C., Lipton, R.B. , Chou, Sherry H-Y , Seshadri, Sudha , Snyder, Heather M , Yaffe, Kristine , Zachrison, Kori S , Cogswell, Petrice M. , Hicks, William J., Massimo, Lauren , Seshadri, Sudha , Atri, Alireza, Blum, Sonja, Bussière, Thierry , Carlisle, Tara C. , Chaitoff, Alexander , Cruz-Flores, Salvador, Chyou, Janice Y. , Derdeyn, Colin P. , Gettel, Cameron J. , Goldstein, Larry B. , Grill, Joshua D. , Ishii, Makoto , Kulshreshtha, Ambar , Rabinstein, Alejandro A. , Ramanan, Vijay K. , McCullough, Louise D. , Merino, José G. , Messé, Steven R. , Ruff, Christian Thomas , Saklad, Stephen R. , Selim, Magdy H. , Shah, Sachin J. , Stamm, Brian , Buckwalter, Marion S. , Skylar-Scott, Irina A., Rabinovici, Gil D. , VandeVrede, Lawren , Chatterjee, Arindam R , Wunderink, Richard G.

Mayo Clinic

Journal of the American Heart Association | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.125.048108 | PMID 42622140 Get It

Background New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. Methods The American Heart Association convened 75 multidisciplinary experts for the Amyloid‐Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus‐based guidance for clinicians. Results This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co‐occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision‐making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. Conclusions Building on lessons learned from the establishment of stroke systems of care, the consensus‐based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground‐breaking therapies.
American Society of Hematology 2026 Guidelines for Immune Thrombocytopenia (ITP): Initial and Second-Line Therapy in Adults with Primary ITP
Cuker, Adam, Terrell, Deirdra R. , Sowdagar, Honieh, Arnold, Donald M. , Audia, Sylvain , Bussel, James B. , González‐López, Tomás José , Masias, Camila , McCrae, Keith R. , Panch, Sandhya , Shah, Surbhi, Shy, Brenda G, Vandevelde, Jessica , Grace, Rachael F , McCrae, Keith R , Mitrovic, Mirjana , Neunert, Cindy E. , Panch, Sandhya Ramanathan , Cines, Douglas B , Vesely, Sara K , Arnold, Donald M , Terrell, Deirdra R , Cuker, Adam , González‐López, Tomás José , Grace, Rachael F. , VandeVelde, Jessica

Mayo Clinic

Blood Advances | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021269 | PMID 42617047 Get It

Background: Since publication of the American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia (ITP), new clinical trials have been completed and new treatments have become available. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) are a focused update of the 2019 ASH ITP guidelines, centering on treatment of adults with primary ITP. Methods: ASH formed a multidisciplinary guideline panel including two patient representatives that was balanced to minimize potential bias from conflicts of interest. The University of Oklahoma supported the guideline development process, including updating or performing systematic evidence reviews (up to July 19, 2025). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and identification of areas with new data or where application of new methods would be of benefit. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks and the GRADE framework for multiple comparisons, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on recommendations in adults with primary ITP regarding initial therapy and second-line treatment in patients who failed first-line corticosteroids. The panel also issued good practice statements on thrombopoietic agent switching and splenectomy. Conclusions: Novel recommendations of these guidelines include: (1) initial therapy with a combination of rituximab plus corticosteroids or a thrombopoietic agent plus corticosteroids rather than corticosteroids alone (conditional recommendation) and (2) a thrombopoietic agent (strong recommendation) or rituximab (conditional recommendation) for patients who failed first-line corticosteroids.
Tissue and blood-based predictive biomarkers in hepatocellular carcinoma immunotherapy: synthesis of 2023–2026 evidence and a proposed clinical integration framework
Sisodia, Rajvardhan , Bharadwaj, Hareesha Rishab , Sonaiya, Sneh, Shah, Yash, Dhali, Arkadeep, Abdul, Rahman, Khan, Sajjad Ahmad, Alsakarneh, Saqr, Mandal, Saikat, Bharadwaj, Hareesha Rishab , Sharma, Ashish , Tan, Joecelyn Kirani , Kumar, Harendra , Sonaiya, Sneh , Ali, Hassam , Dhali, Arkadeep , Alsakarneh, Saqr , Dahiya, Dushyant Singh , Mandal, Saikat

Mayo Clinic

Frontiers in Oncology | August 19, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1894185 | PMID 42689129 Get It

Atezolizumab-bevacizumab and durvalumab-tremelimumab have established immunotherapy as a first-line standard of care in advanced hepatocellular carcinoma (HCC). Yet, objective response rates (ORRs) remain confined to approximately 15-20%, and no validated predictive biomarker exists for patient selection. Unlike melanoma and lung cancer, conventional markers, including programmed death-ligand 1, microsatellite instability-high status, and tumor mutational burden, have not demonstrated reliable predictive value in HCC. Prior narrative reviews comprehensively catalogued the biomarker landscape through 2022 but predate a wave of clinically significant publications. This narrative review synthesizes evidence published between 2020 and 2026, with particular emphasis on 2023–2026 data, within a unified clinical framework not provided by prior reviews. We critically evaluate tissue-based biomarkers, including the AI-derived Atezolizumab-Bevacizumab Response Signature-Pathology model, spatial multiplex immunohistochemistry, and β-catenin mutational profiling; blood-based biomarkers encompassing circulating tumor DNA for minimal residual disease detection and peripheral immune phenotyping; and serum indices including the CRAFITY score and neutrophil-to-lymphocyte ratio. Hepatitis B virus etiology and non-alcoholic steatohepatitis are discussed as biological modifiers of biomarker performance. We propose an original biomarker-guided clinical algorithm, a comparative clinical readiness table, and a disease-continuum biomarker timeline as practical tools for clinicians and trialists. Prospective biomarker-enrichment trials represent the most critical next step toward clinical translation.
Validation of the Semi-Quantitative MRI (SQ-MRI) Score as a Biomarker for Non-Calcific Chronic Pancreatitis in a Multicenter Cohort
Tirkes, Temel, Chang, Stephanie T., Mawad, Kareem , Shah, Zarine K. , Venkatesh, Sudhakar K., Wachsman, Ashley, Li, Liang, Li, Shuang, Easler, Jeffrey, Fogel, Evan L. , Forsmark, Christopher E. , Hart, Phil A., Pandol, Stephen J., Park, Walter G., Topazian, Mark, Trikudanathan, Guru, Vege, Santhi Swaroop, Conwell, Darwin L., Yadav, Dhiraj, Tirkes, Temel , Dasyam, Anil K. , Spilseth, Benjamin , Takahashi, Naoki , Venkatesh, Sudhakar K. , Easler, Jeffrey J. , Forsmark, Chris E. , Hart, Phil A. , Pandol, Stephen J , Park, Walter G., Trikudanathan, Guru , Van Den Eeden, Stephen K , Vege, Santhi Swaroop , Conwell, Darwin L. , Yadav, Dhiraj

Mayo Clinic

No container title available | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10504233/v1 Get It

Abstract Purpose Validate the semiquantitative (SQ)-MRI score for chronic pancreatitis (CP) diagnosis in an independent, multicenter cohort. Methods We analyzed MRIs performed at baseline in 337 participants with acute (AP) or recurrent AP (RAP) and 67 with non-calcific chronic pancreatitis (NCCP) enrolled in the PROCEED study from 6/2017 to 3/2023. MRIs were performed at multiple clinical centers using site-specific clinical protocols and a variety of MRI vendors to evaluate the SQ-MRI score in a real-world setting. The SQ-MRI score was calculated using the T1 signal intensity ratio of the pancreas to the spleen (T1 score), arteriovenous enhancement ratio (AVR), and pancreatic body diameter (PBD). We adjusted for confounding by participant characteristics via propensity score weighting. Results Median AVR was higher in AP/RAP (1.18, IQR: 0.97–1.44) than in the NCCP group (1.03, IQR: 0.78–1.22, p = 0.007). Pancreatic body diameters were larger in AP/RAP than in the NCCP group − 7–14 mm (10% vs 25%), 14–20 mm (40% vs 54%), and > 20 mm (50% vs 21%), respectively ( p < 0.01). Median T1 score was higher in AP/RAP (1.18, IQR: 0.96–1.40) than in the NCCP group (1.04, IQR: 0.86–1.32, p = 0.10). Median SQ-MRI score in the AP/RAP group was significantly lower, 1.91 (IQR: 0.97, 2.95), than in the NCCP group, 2.74 (IQR: 2.04–4.03) ( p < 0.001). The propensity score-adjusted AUC for SQ-MRI to distinguish AP/RAP from NCCP was 0.64, which was higher than for individual parameters. Conclusion We have validated the SQ-MRI score in a multicenter cohort using an independent, real-world MRI dataset.
Cerebellar tonsillar ectopia: Navigating intracranial hypertension and hypotension in a pediatric patient
Lai, Sammie , Nguyen, Sarah, Pandya, Jay, Taskin, Didem, Hana, Leticia Schafer Abu, Shah, Chetan, Kim, J H , Nguyen, Sarah, Shah, Chetan

Mayo Clinic

Cephalalgia Reports | August 18, 2026 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/25158163261478626 Get It

Background Cerebellar tonsillar ectopia may arise from altered cerebrospinal fluid (CSF) dynamics and can mimic Chiari I malformation. Differentiating between pressure-induced tonsillar descent and congenital malformations is essential. We present an interesting case that visualizes variable tonsillar displacement levels as an indicator of CSF dynamics. Case A 3-year-old boy presented with headache and sixth nerve palsy and was diagnosed with idiopathic intracranial hypertension. Initial magnetic resonance imaging (MRI) revealed a 5 mm descent of the cerebellar tonsils. During hospitalization, the patient underwent mastoidectomy for an incidental T2 hyperintense lesion. Subsequent MRI scans demonstrated the resolution of tonsillar displacement. At age 5, the patient experienced worsening headache. Brain MRI revealed a 13 mm descent of the cerebellar tonsils below the foramen magnum and pachymeningeal enhancement. Further evaluation revealed transtemporal CSF leakage through the previous mastoidectomy site into the soft neck tissues. Conclusion This case exemplifies cerebellar tonsillar displacement associated with both intracranial hypertension (push) and hypotension (pull), illustrating opposite causal directions of CSF dynamics in the same patient. Understanding the phenomenon as a result of dynamic CSF balance rather than unidirectional force or fixed pathophysiology can enhance monitoring of patients.
Characterization of Ventilator-Associated Pneumonia in Patients Receiving Extracorporeal Membrane Oxygenation Support
Kim, Myeongji , Lynn-Green, Erika E , Igwilo-Alaneme, Rita I., Marcus, Joseph E , Lyster, Haifa, Seelhammer, Troy G. , Riera, Jordi, Shah, Aditya, Bohman, John Kyle, Marcus, Joseph , Ranganath, Nischal , Wieruszewski, Patrick M. , Lynn-Green, Erika , Igwilo-Alaneme, Rita , Lyster, Haifa S. , Bohman, J. Kyle , Riera, Jordi

Mayo Clinic

ASAIO Journal | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mat.0000000000002820 | PMID 42606818 Get It

In this retrospective cohort study at a quaternary referral hospital, 829 adult patients supported by extracorporeal membrane oxygenation (ECMO) between January 1, 2014, and October 31, 2024, were screened for ventilator-associated pneumonia (VAP). The incidence of VAP in ECMO-supported patients was 17.7 per 1,000 ECMO days (venoarterial [VA] ECMO, 22.1 per 1,000 ECMO days; venovenous [VV] ECMO, 13.8 per 1,000 ECMO days). Median time from ECMO cannulation to diagnosis of VAP was 4 (interquartile range [IQR], 3–8; range 1–84) days. Gram-negative bacteria comprised most respiratory pathogens. A significant increase in minimum ECMO sweep was noted from 2 days before to 1 day after VAP diagnosis (0.79 L/min increase, p = 0.004). Only 38 of 153 patients (24.8%) met National Healthcare Safety Network (NHSN) VAP definitions. After creating a modified VAP definition, which included an ECMO sweep increase of 0.5 L/min as evidence of worsening respiratory status, 78 (51.0%) met the modified definition. Those who met the modified VAP definition had worse in-hospital (60.3% vs. 28.0%, p < 0.001), 30 day (33.3% vs. 17.3%, p = 0.023), and 90 day (53.8% vs. 25.3%, p < 0.001) mortality compared with those who did not meet the modified VAP definition. The incorporation of ECMO parameters into diagnostic criteria may improve detection sensitivity, but further validation is necessary before implementation.
Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography
Li, Jiahui , Wu, Hao , Glaser, Kevin J. , Ou, Fang‐Shu , Manduca, Armando , Venkatesh, Sudhakar K. , Sirlin, Claude B. , Shah, Vijay H. , Ehman, Richard L. , Wu, Hao , Sirlin, Claude B. , Loomba, Rohit , Ehman, Richard , Allen, Alina M , Manduca, A , Ou, Fang-Shu , Venkatesh, Sudhakar K , Li, Jiahui , Loomba, Rohit , Allen, Alina M. , Yin, Meng , Wu, Hao

Mayo Clinic

Hepatology Communications | August 11, 2026 | Volume: 10 | Issue: 9 | Pages: No page available

10.1097/hc9.0000000000001024 | PMID 42579768 Get It

Background: Accurate identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) at risk of disease progression (at-risk MASH) is critical for guiding resmetirom and semaglutide therapy. Inconsistent definitions of at-risk MASH complicate clinical risk classification and comparisons across studies. This study aimed to standardize the definition of at-risk MASH and propose optimized MRE-based liver stiffness (LS-MRE) cutoffs to improve noninvasive risk stratification and better guide pharmacotherapy. Methods: In this prospective study, 413 patients with suspected or diagnosed MASLD from two medical centers underwent liver biopsy and MRE. Results: A simplified definition of at-risk MASH (MASH with fibrosis stage≥2) identified a broader group of patients requiring clinical attention than a stricter definition requiring NAFLD Activity Score≥4 with ≥1 point in steatosis, inflammation, and ballooning (n=122 vs. 77). LS-MRE alone showed the highest diagnostic accuracy for identifying at-risk MASH using the simplified definition (AUC 0.91 [0.87, 0.95]) and cirrhosis (AUC 0.93 [0.88, 0.99]), compared with FIB-4 and individual laboratory parameters (AST, ALT, and platelet count) ( p <0.01 for all, paired DeLong tests). Optimized LS-MRE cutoffs (2.8–6.4 kPa) captured 25 additional biopsy-proven pharmacotherapy candidates (28% of all eligible patients) compared to AASLD guidelines–recommended cutoffs (3.1–4.4 kPa), improving sensitivity (80% vs. 50%) with acceptable specificity (73% vs. 88%). Conclusions: A simplified definition of at-risk MASH enables broader identification of treatment candidates. LS-MRE demonstrates excellent diagnostic performance and improves noninvasive risk stratification when paired with optimized cutoffs. These findings support the use of MRE to guide resmetirom and semaglutide eligibility and improve access to emerging therapies.
Oral administration of dibenzoylmethane (DBM) prevents cognitive decline in a C9ORF72-mediated FTD mouse model
Torres, Paulina, Becerra, Daniela, Astorga, José I., Kauwe, Grant, Gonzalez, Luis, Diaz, Guillermo, Morales, Vania, Valenzuela, Vicente, Wehrfritz, Cameron, Ngwala, Yani Y., Sepúlveda-Quiñenao, Claudia, Shah, Samah , Petrucelli, Leonard , Hetz, Claudio , Torres, Paulina , Fuentealba, Matías , Bons, Joanna , Tracy, Tara E. , Schilling, Birgit , Hetz, Claudio , Petrucelli, Leonard

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.07.743573 | PMID 42845299 Get It

Abstract Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related neurodegenerative disorders that display overlapping features. The hexanucleotide repeat expansion GGGGCC (G 4 C 2 ) in the C9ORF72 gene is the most common cause of ALS and FTD, which results in the accumulation of dipeptide-repeat protein aggregates. Regulation of protein synthesis at the level of the initiation factor eIF2α has been suggested as a transversal event contributing to neurodegeneration in ALS and FTD. eIF2α phosphorylation blocks protein synthesis to alleviate protein misfolding overload, but conversely it can reduce the expression of synaptic proteins resulting in neuronal dysfunction. Dibenzoylmethane (DBM) is a small molecule that reverses the translational attenuation mediated by eIF2α phosphorylation which has been shown to alleviate neurodegeneration in prion-infected mice and Tau transgenic animals. Here we investigated the efficacy of the oral administration of DBM in protecting a mouse model of C9ORF72 pathogenesis. Treatment of mice with 0.5% of DBM mixture in powdered food ad libitum was sufficient to prevent cognitive impairment in C9ORF72 mice. Unexpectedly, DBM treatment did not modify the content of poly(GA) and poly(GR) protein inclusion in the hippocampus and brain cortex. Proteomic profiling of brain tissue indicated that DBM administration corrected nearly 70% of the changes in gene expression triggered by expanded G 4 C 2 , where the main pathways modified by DBM were related to cytoskeleton organization, ALS, and metabolic processes. Most proteins corrected by DBM in our C9ORF72 model were also altered in the brain of human FTD/ALS patients. Overall, our results reinforce the idea that targeting protein synthesis with small molecules in patients carrying C9ORF72 mutations may result in improved cognitive capacity.
Short‐Term Risk Stratification in Alcohol‐Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End‐Stage Liver Disease
Vilar‐Gómez, Eduardo , Connelly, Margery A. , Shah, Vijay H. , Shalaurova, Irina, Rafalko, Jill M. , Sanyal, Arun J. , Chalasani, Naga , Gawrieh, Samer , Chalasani, Naga , Sanyal, A J , Gawrieh, Samer , Vilar-Gomez, Eduardo

Mayo Clinic

Alcohol, Clinical and Experimental Research | August 10, 2026 | Volume: 50 | Issue: 8 | Pages: No page available

10.1111/acer.70388 | PMID 42572151 Get It

ABSTRACT Background Alcohol‐associated hepatitis (AH) has high short‐term mortality, whereas current prognostic models mainly reflect liver and renal dysfunction. The Metabolic Vulnerability Index (MVX) is a nuclear magnetic resonance‐derived score comprising the Inflammation Vulnerability Index (IVX; small high‐density lipoprotein particles [S‐HDL‐P] and GlycA) and the Metabolic Malnutrition Index (MMX). We evaluated whether MVX, IVX, and IVX components improve 90‐day mortality prediction beyond Model for End‐Stage Liver Disease (MELD) in AH. Methods Serum samples from 196 patients with AH, 169 heavy‐drinking controls, and 351 healthy controls were analyzed by nuclear magnetic resonance spectroscopy. The primary outcome was 90‐day AH‐related mortality. Biomarkers were modeled continuously after standardization within the AH cohort; S‐HDL‐P was modeled per 1 SD decrease. Cox models were adjusted for MELD, age, sex, white blood cell count, and baseline antibiotic or corticosteroid use. Model performance was assessed using Akaike information criterion (AIC), likelihood‐ratio testing, and Harrell's C ‐statistic. Results Among patients with AH, 30 AH‐related deaths occurred within 90 days (15.3%). IVX and MVX were highest in AH cases and increased with AH severity, whereas MMX did not consistently differentiate severity. Lower S‐HDL‐P was independently associated with 90‐day mortality in fully adjusted models (HR, 1.84; 95% CI, 1.01–3.35; p = 0.045), whereas GlycA was not (HR, 0.86; 95% CI, 0.54–1.37; p = 0.527). Adding S‐HDL‐P improved fully adjusted MELD‐based model fit (AIC, 298.97 vs. 301.46; LR p = 0.034; C ‐statistic, 0.741 vs. 0.729). IVX showed supportive improvement in model fit and discrimination (AIC, 299.81; LR p = 0.056; C ‐statistic, 0.749). Continuous MELD interaction analyses supported risk separation for S‐HDL‐P (LR χ 2 = 6.20; p = 0.045) and IVX (LR χ 2 = 6.64; p = 0.036). Conclusions Lower S‐HDL‐P appears to be the principal short‐term prognostic component within the IVX domain in AH. S‐HDL‐P and IVX may refine MELD‐based 90‐day risk stratification, pending external validation.